 Chemical Structure.png)
AT2 Agonist C21 (M-24) is a novel, potent and selective agonist of angiotensin AT2 receptors with Ki values of 0.4 nM and >10 µM for the AT2 receptor and AT1 receptor, respectively. It inhibits leukocyte adhesion and endothelial inflammation both in vivo and in vitro.
Physicochemical Properties
| Molecular Formula | C23H29N3O4S2 |
| Molecular Weight | 475.6241 |
| Exact Mass | 475.159 |
| Elemental Analysis | C, 58.08; H, 6.15; N, 8.83; O, 13.46; S, 13.48 |
| CAS # | 477775-14-7 |
| PubChem CID | 9804984 |
| Appearance | White to yellow solid powder |
| Density | 1.3±0.1 g/cm3 |
| Index of Refraction | 1.615 |
| LogP | 4.93 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 11 |
| Heavy Atom Count | 32 |
| Complexity | 690 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | S1C(=C(C2C([H])=C([H])C(C([H])([H])N3C([H])=NC([H])=C3[H])=C([H])C=2[H])C([H])=C1C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])S(N([H])C(=O)OC([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])(=O)=O |
| InChi Key | XTEOJPUYZWEXFI-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C23H29N3O4S2/c1-4-5-12-30-23(27)25-32(28,29)22-21(14-20(31-22)13-17(2)3)19-8-6-18(7-9-19)15-26-11-10-24-16-26/h6-11,14,16-17H,4-5,12-13,15H2,1-3H3,(H,25,27) |
| Chemical Name | butyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate |
| Synonyms | M 24; Buloxibutid; AT2 Agonist C21; C21; M24; M-24; C-21; C 21; AT2 receptor agonist C21 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | AT2 Receptor ( Ki = 0.4 nM ); AT1 Receptor ( Ki > 10 μM ) |
| ln Vitro | Buloxibutid stimulates p42/p44mapk, increases in vivo duodenal alkaline secretion in Sprague-Dawley rats, induces neurite cell outgrowth, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats. Its half-life in rats is estimated to be 4 hours. |
| ln Vivo | Buloxibutid has a bioavailability of 20-30% after oral administration, and its half-life in rats is estimated to be 4 hours. It can induce neurite cell growth, stimulate p42/p44mapk, and enhance duodenal alkaline secretion in Sprague-Dawley rats. and reduced mean arterial blood pressure in anesthetized spontaneously hypertensive rats [1]. |
| References |
[1]. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004 Nov 18;47(24):5995-6008. [2]. Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice. J Mol Med (Berl). 2016;94(8):957-966. [3]. Angiotensin AT2 Receptor is Anti-inflammatory and Reno-Protective in Lipopolysaccharide Mice Model: Role of IL-10. Front Pharmacol. 2021;12:600163. |
Solubility Data
| Solubility (In Vitro) | DMSO: ~100 mg/mL (~210.3 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1025 mL | 10.5126 mL | 21.0252 mL | |
| 5 mM | 0.4205 mL | 2.1025 mL | 4.2050 mL | |
| 10 mM | 0.2103 mL | 1.0513 mL | 2.1025 mL |